-+ 0.00%
-+ 0.00%
-+ 0.00%

VERASTEM ONCOLOGY DOSES FIRST PATIENT IN TARGET-D 202 PHASE 2 REGISTRATION-DIRECTED TRIAL OF VS-7375 FOR KRAS G12D-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Reuters·07/22/2026 20:01:00

Please log in to view news